Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy
International Journal of Molecular Sciences · 16.01.2026 · 27 (2) · 909
DOI: 10.3390/ijms27020909 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.01.2026. Verfasst von Mouldy Sioud und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, Department of Cancer Immunology, Oslo University Hospital-Rdiumhospitalet, Ullernchausseen 70, 0379 Oslo, Norway. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Norwegian Cancer Society.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative form of immunotherapy, enabling the precise engineering of T cells to recognize and eliminate pathogenic cells. In hematologic malignancies, CAR-T cells targeting CD19 or B cell maturation antigens have achieved remarkable remission rates and durable responses in patients with otherwise refractory disease. Despite these successes, extending CAR-T cell therapy to solid tumors remains challenging due to antigen heterogeneity, poor T cell infiltration, and the immunosuppressive tumor microenvironment (TME). Beyond oncology, CAR-T cell therapy has also shown promise in autoimmune diseases, where early clinical studies suggest that B cell-directed CAR-T cells can induce sustained remission in conditions such as systemic lupus erythematosus. This review highlights advances in CAR-T cell engineering, including DNA- and mRNA-based platforms for ex vivo and in vivo programming, and discusses emerging strategies to enhance CAR-T cell trafficking, persistence, and resistance to TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Medicine, Department of Cancer Immunology, Oslo University Hospital-Rdiumhospitalet, Ullernchausseen 70, 0379 Oslo, Norway.
ORCID-Profile: Nicholas Paul Casey
Förderung
- The Norwegian Cancer Society
Zitieren
APA
Sioud, M., & Casey, N. P. (2026). Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy. International Journal of Molecular Sciences, 27(2), 909. https://doi.org/10.3390/ijms27020909
Vancouver
Sioud M, Casey NP. Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy. International Journal of Molecular Sciences. 2026;27(2):909. doi:10.3390/ijms27020909
BibTeX
@article{Sioud2026,
author = {Sioud, Mouldy and Casey, Nicholas Paul},
title = {Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {909},
doi = {10.3390/ijms27020909}
}
EUVIMED